Abstract: The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.

Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

Abstract: A method for extracting stem cells from a non-embryonic stem cell source, including providing a non-embryonic stem cell source including stem cells; perfusing the non-embryonic stem cell source with a pulsatile flow of a perfusion solution to produce a perfusate including stem cells and a perfused non-embryonic stem cell source; and isolating the stem cells from the perfusate to produce isolated stem cells, is provided. Also provided is a non-embryonic stem cell line derived from a non-embryonic stem cell obtained using the pulsatile perfusion extraction method.

Abstract: Rich tooling is provided for REST application development that integrates the exploration of a REST API, modeling of data types and the REST API, and the generation of artifacts using the modeled REST API and data types.

Abstract: The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer.

Abstract: The present invention relates to a method of using a TAFA4 protein or an agonist thereof for preventing, alleviating or treating pain in a subject. In one embodiment, the invention provides a method of treating pain in a subject by administering a TAFA4 protein or an agonist thereof to the subject. The TAFA4 can have the amino acid sequence of SEQ ID NO: 1 or 2 or a sequence having at least 90% sequence identity to SEQ ID NO: 1 or 2. The TAFA4 agonist can also be a peptide comprising 10 to 60 consecutive amino acid residues of SEQ ID NO: 1 or 2. Also described herein are pharmaceutical compositions, their preparation and uses as well as methods for preventing, alleviating or treating pain using such compounds and compositions.

Abstract: The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm.

Abstract: The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes.

Abstract: The current invention discloses a genetically engineered bacterium used for the treatment of breast cancer. The said bacterium is attenuated Salmonella typhimurium VNP20009 with cloned L-methioninase gene. The method for constructing this genetically engineered bacterium and the application thereof are also disclosed herein. In the current invention, our biologic drug for the treatment of breast cancer is a type of safe, non-toxic new drug with anti-tumor activity. It can highly express methioninase through recombinant DNA technology using attenuated Salmonella typhimurium VNP20009 as a carrier, which has a strong anti-tumor activity and can meet the needs. The preparation method is simple and easy to operate, showing good application prospect.

Abstract: This disclosure relates to nanoparticles carrying nucleic acid cassettes for expressing RNA. In certain embodiments, the disclosure relates to improved methods for targeted delivery and expression of siRNAs in vivo using DNA-based siRNA-expressing nanocassettes and receptor-targeted nanoparticles. In certain embodiments, the disclosure relates to methods of targeted delivery of survivin siRNA expressing nanocassettes which enhance sensitivity of human cancer cells to anticancer agents.

Abstract: Provided are a modified laminin having a cell-growth regulatory molecule bound to at least one site selected from the ? chain N-terminus, the ? chain C-terminus, the ? chain N-terminus and the ? chain N-terminus of laminin or a heterotrimeric laminin fragment, a method for culturing cells in the presence of the modified laminin, a method for establishing iPS cells in the presence of the modified laminin, and a culture substrate coated with the modified laminin. Human stem cells cultured in a xeno-free environment with the use of the modified laminin of the present invention can be provided as highly safe human stem cells applicable to regenerative medicine.

Abstract: The present invention relates to a therapeutic substance and/or medicament and methods relating to the use of said substance and/or medicament for skeletal muscle regeneration using mesenchymal stem cells (MSCs) which can be applied directly or shortly after muscle damage or injury.

Abstract: The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.

Abstract: A bone patch and method for treating a bone condition of an animal. The bone patch includes a composition of ingredients. The composition of ingredients include: stem cells; signaling molecules for osteoblast/endothelial differentiation; and scaffold material. The method for treating a bone condition includes: applying the bone patch to the animal for bone regeneration, treatment of a fractured bone, and/or treatment of a bone disorder.

Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

Abstract: The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.

Abstract: Disclosed herein are methods and compositions for insertion of Factor IX (FIX) sequences into the genome of a cell for treating hemophilia B.

Abstract: The present invention relates to methods and compositions for diagnosing a disease or disorder in a subject by introducing into cells of the subject a diagnostic gene switch construct and monitoring expression of a reporter gene. The invention further relates to methods and compositions for monitoring the progression of a disease or disorder or the effectiveness of a treatment for a disease or disorder.

Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

Abstract: Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro, and methods of use thereof. The cells may be provided in a three dimensional matrix for culturing in vitro and/or implanting in vivo. Methods of seeding cells onto the matrix are also provided.